Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01107899
Other study ID # 11983
Secondary ID H7T-MC-TACM
Status Terminated
Phase Phase 1
First received April 19, 2010
Last updated March 7, 2012
Start date October 2009
Est. completion date December 2010

Study information

Verified date March 2012
Source Eli Lilly and Company
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To investigate how platelets recover to normal function in subjects who have symptoms of a heart attack or unstable angina and who get a loading dose of prasugrel or clopidogrel for planned coronary angiography.


Recruitment information / eligibility

Status Terminated
Enrollment 29
Est. completion date December 2010
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 79 Years
Eligibility Inclusion Criteria:

- Men or women =18 to <80 years of age who present with any one of the following:

- symptoms of Acute Coronary Syndromes (ACS)

- clinical symptoms of angina, or a positive stress test or who return for routine follow up angiography post stent placement in whom co-administration of aspirin and a thienopyridine (that is, clopidogrel, ticlopidine, or prasugrel) is not contraindicated

Exclusion Criteria:

- Those presenting with ST-elevation MI (STEMI)

- histories of refractory ventricular arrhythmias

- an implanted defibrillator device

- congestive heart failure (NYHA Class III or above) within 6 months prior to screening

- significant hypertension

- subjects with a history or clinical suspicion of cerebral vascular malformations, transient ischaemic attack, or stroke

- bleeding disorders

- women known to be pregnant, who have given birth within the past 90 days, or who are breastfeeding

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
clopidogrel
taken orally, day one, single dose
prasugrel
taken orally, day one, single dose

Locations

Country Name City State
Germany For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Munich

Sponsors (2)

Lead Sponsor Collaborator
Eli Lilly and Company Daiichi Sankyo Co., Ltd.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Returning to Baseline Platelet Function Participants were classified as having platelet function return to baseline after loading dose (LD) on the first day that P2Y12 Reaction Units (PRU) was no more than 60 PRU below baseline and remained in this range. PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of adenosine diphosphate (ADP)-stimulated platelet aggregation. Days 3, 5, 7, 9, and 11 Yes
Secondary The Day on Which 50%, 75% and 90% of Subjects Return to Baseline Platelet Function Following a Single LD of 30-mg or 60-mg Prasugrel or 600-mg Clopidogrel This outcome measure was not analyzed due to the limited sample size. Up through 11 days Yes
Secondary The Day When the Proportion of Participants Who Return to Baseline Platelet Function in the 30-mg and 60-mg Prasugrel Groups is Similar to the 600-mg Clopidogrel Group at Day 5 and Day 7 The day at which the proportion of participants who return to baseline platelet P2Y12 receptor function in the prasugrel 30 mg and 60 mg LD groups is similar (within 10% absolute difference) to the proportion of subjects who return to baseline platelet P2Y12 receptor function at day 5 and day 7 in the clopidogrel 600 mg LD group, obtained from Kaplan Meier curves for the primary washout population, was to be presented. This outcome measure was not analyzed due to the limited sample size. Up through 11 days Yes
Secondary Number of Days to the Return of Baseline Platelet Function Following One Loading Dose (LD) The return of baseline platelet function following one LD of prasugrel (30 mg or 60 mg) or 600 mg LD of clopidogrel assessed by Verify Now™ P2Y12 Reaction Units (VN-PRU). This outcome measure was not analyzed because it was not appropriate to estimate the days based on the non-inferiority approach due to the limited sample size. Up through 11 days Yes
Secondary Effect of Initial Inhibition of Platelet Aggregation on the Day to Return to Baseline Platelet Function: VN-PRU To show effect of initial inhibition of platelet aggregation as measured by Accumetrics Verify Now™ P2Y12 on the day to return to baseline platelet function, a regression model was fitted with day to return as outcome variable and initial inhibition as fixed effect. Results are reported as the predicted day to return to baseline platelet function by derived VN-PRU percent (%) inhibition at 24 hours post LD. The derived VN-PRU % inhibition is calculated as a percent decrease of PRU from baseline using the following formula: ([PRU at baseline - PRU at 24 hours post LD]/PRU at baseline) x 100%. Up through 11 days Yes
Secondary Mean Number of Days to the Return of Baseline Platelet Function in All Treatment Arms (Adjusted for Level of Inhibition 24 Hrs Post-LD) by VN-PRU PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of adenosine diphosphate (ADP)-stimulated platelet aggregation. This outcome measure was not analyzed due to the limited sample size. Up through 11 days Yes
Secondary Platelet Function 24 Hours Post Loading Dose PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of ADP-stimulated platelet aggregation. 24 hours post-loading dose Yes
Secondary Percentage of Poor Pharmacodynamic Responders by Platelet Aggregation at 24 Hours Post-LD Platelet aggregation was assessed by Accumetrics Verify Now™ P2Y12, and poor responders were those with PRU greater than or equal to 230. 24 hours post-loading dose Yes
Secondary Extent of Initial Inhibition of Platelet Aggregation on the Return of Baseline Platelet Function: Light Transmission Aggregometry (LTA) Initial inhibition of platelet aggregation was measured by LTA at 5 and 20 µM ADP. Maximum platelet aggregation (MPA) is reported by day. Up through 11 days Yes
Secondary Extent of Initial Inhibition of Platelet Aggregation to the Return of Baseline Platelet Function: Multiplate® ADP Test and ADP Test High Sensitivity (HS) Return of baseline platelet function was assessed by Multiplate® ADP test and ADP test High Sensitivity (HS). Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. The agonist ADP was added to stirred whole blood after dilution (1:2 with 0.9% NaCl solution) in a final concentration of 6.4 µM (ADP Test) or in final concentration of 6.4 µM ADP plus 9.4 nM Prostaglandin E1 (PGE1) (ADPtest HS). Platelet aggregation was continuously recorded for 5 minutes and quantified as area under the aggregation curve (AUC=AU*min) of aggregation units (AU). Up through 11 days Yes
Secondary Mean Number of Days to the Return of Baseline Platelet Function in All Treatment Arms (Adjusted for Level of Inhibition 24 Hours Post-LD) by LTA (5 and 20 µM ADP) Maximum platelet aggregation (MPA) to 5 and 20 µM ADP were assessed by LTA. This outcome measure was not analyzed due to limited sample size. Up through 11 days Yes
Secondary Mean Number of Days to the Return of Baseline Platelet Function in All Treatment Arms (Adjusted for Level of Inhibition 24 Hrs Post-LD) by Multiplate® ADP Test and ADP Test High Sensitivity (HS) The Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. After adding 6.4 µM ADP (ADP test) or 6.4 µM ADP plus 9.4 nM Prostaglandin E1 (PGE1) (ADP test HS), area under the aggregation curve (AUC) was calculated. This outcome measure was not analyzed due to limited sample size. Up through 11 days Yes
Secondary Platelet Function by LTA at 5 and 20 µM ADP MPA to 5 and 20 µM ADP were assessed by LTA. 24 hours post-loading dose Yes
Secondary Platelet Function by Multiplate® ADP Test and ADP Test HS The Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. After adding 6.4 µM ADP (ADP test) or 6.4 µM ADP plus 9.4 nM PGE1 (ADP test HS), area under the aggregation curve (AUC) were calculated. 24 hours post-loading dose Yes
See also
  Status Clinical Trial Phase
Completed NCT02552407 - Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis N/A
Completed NCT01398228 - Clinical Pathways for the Management of Acute Coronary Syndromes - Phase 3,CPACS-3 N/A
Completed NCT01135667 - Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI Phase 4
Recruiting NCT02592720 - Cocktail Injection Improves Outcomes of FFR Guided PCI Phase 4
Completed NCT01641510 - PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants Phase 3
Completed NCT01743274 - Does Optical Coherence Tomography Optimise Results of Stenting N/A
Active, not recruiting NCT01433627 - Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX Phase 3
Completed NCT01452282 - Ankle-Brachial Index Estimating Cardiac Complications After Surgery N/A
Recruiting NCT01418794 - Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Phase 4
Recruiting NCT01000701 - Inflammation and Acute Coronary Syndromes N/A
Completed NCT00494247 - Endothelial Progenitor Cells-capture Stents in Acute Coronary Syndromes Phase 4
Terminated NCT00615719 - Computed Tomographic Coronary Angiography for Acute Chest Pain Evaluation N/A
Active, not recruiting NCT06089343 - High-risk Features of Coronary Lesions in CTA and OCT
Not yet recruiting NCT04023630 - DUAL Antithrombotic Therapy in Patients With AF and ACS Phase 4
Recruiting NCT02601404 - REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD) N/A
Completed NCT02195193 - Integrating Depression Care in Acute Coronary Syndromes Care in China N/A
Not yet recruiting NCT01735227 - Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN) Phase 4
Completed NCT02141750 - THIRD NATIONAL REGISTRY OF ACUTE CORONARY SYNDROMES N/A
Completed NCT00097591 - A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention Phase 3
Completed NCT02725099 - Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients Phase 4